New publication: Durable clinical responses in stage III–IV non-small-cell lung cancer patients treated with IDO peptide vaccine in a phase I study

Sep 28, 2018

Copenhagen, Denmark – September 28, 2018: IO Biotech has published a brief research report describing long term follow-up of phase I study in stage III-IV NSCLC in “Frontiers in Immunology”

Other news

IO Biotech Announces Appointment of Devin Smith as General Counsel

IO Biotech Announces Appointment of Devin Smith as General Counsel

IO Biotech Provides Business Update

IO Biotech Provides Business Update